Clinical trials: Major Depressive Disorder, Recurrent
Major Depressive Disorder, Major Depressive Episode
MRS and Medication Response: A Pilot Study
We hope to demonstrate that magnetic resonance spectroscopy can detect brain concentration levels of paroxetine (Paxil) or citalopram (Celexa) or escitalopram (Lexapro) in depressed patients.
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Major Depressive Disorder, Recurrent, Major Depression Mild
- Trial name
- NCT03254342
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Stanford University
Major Depressive Disorder
Wellness Monitoring for Major Depressive Disorder
The Wellness Monitoring for Major Depressive Disorder (MDD) study is a prospective, longitudinal, observational study aimed at identifying biomarkers of relapse in MDD.
- Trial name
- CBN-Well (NCT02934334)
- Testing
- Observational
- Where
- 5 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Sidney Kennedy
Followin Ketamine Treatment
Ketamine Long Therm Follow Up Study
Results of the study and of 5 years follow up of depressed patients who participated in the study during 2014-2015. We will locate the participants and will interview them will use the same questionnaires to evaluate their…
- Trial name
- ket_Fol_Up (NCT04238039)
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- The Chaim Sheba Medical Center
Depressive Disorder, Major
A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00208156
- Testing
- Mifepristone
- Where
- 13 sites in United States
- Volunteers
- 87 people
- Sponsor
- Corcept Therapeutics
Depression, Major Depressive Disorder
Patient Dimensions as Predictors of Varied Treatment Responses and Outcomes in Patients With Major Depression
Depression affects over one million people in Canada, resulting in $14.4 billion per year in costs to Canadian society. In order to prevent this often lifelong disorder, it is critically important to identify risk factors for the…
- Trial name
- NCT00744406
- Testing
- Cognitive Behavioral Therapy, Interpersonal Therapy, Antidepressant medication (sertraline ,paroxetineor or venlafaxine)
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder (MDD)
Predictors of Relapse in Major Depressive Disorder (PERFORM-D)
Major depressive disorder (MDD) is a common condition involving recurring periods of depression. One of the major challenges faced by people with MDD is that the episodes of depression tend to recur even after they are…
- Trial name
- PERFORM-D (NCT06746155)
- Where
- 9 sites in Canada
- Volunteers
- 252 people
- Sponsor
- Abraham Nunes
Major Depressive Disorder, Recurrent
The Effects and Mechanisms of Mindfulness Based Cognitive Therapy (MBCT) on Depressive Symptoms and Depression Relapse
This research proposal is intended to elucidate the efficacy and mechanisms underlying Mindfulness Based Cognitive Therapy (MBCT) in a population in remission from recurrent Major Depressive Disorder (MDD).
- Trial name
- MBCT (NCT01145872)
- Testing
- Mindfulness Based Cognitive Therapy, Health Enhancement Program
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- University of Denver
Major Depressive Disorder, Major Depressive Disorder, Recurrent, Unspecified
Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial
Major depressive disorder (MDD) is a common psychiatric condition, mostly treated with antidepressant drugs, which are limited for issues such as refractoriness and adverse effects.
- Conditions
- Major Depressive Disorder, Major Depressive Disorder, Recurrent, Unspecified, Major Depressive Disorder, Single Episode, Unspecified
- Trial name
- ELECT-TDCS (NCT01894815)
- Testing
- Escitalopram oxalate, transcranial direct current stimulation
- Where
- 2 sites in Brazil
- Volunteers
- 245 people
- Sponsor
- University of Sao Paulo
Major Depressive Disorder
Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder
This primary purpose of this study is to assess the efficacy and safety of Effexor XR in preventing recurrence in Chinese patients with recurrent major depressive disorder (MDD) following a 1-year maintenance treatment after an…
- Trial name
- NCT00878748
- Testing
- Effexor XR, Effexor XR discontinue
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Treatment Resistant Depression, MDD
Psilocybin rTMS for Treatment Resistant Depression
The purpose of this study is to determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with…
- Conditions
- Treatment Resistant Depression, MDD, Major Depressive Disorder, Recurrent Depression
- Trial name
- PSILOBSD (NCT06132178)
- Testing
- Psilocybin, Accelerated intermittent theta burst (aiTBS) rTMS treatment, Low-dose psilocybin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Texas at Austin
Major Depressive Disorder, Recurrent, in Remission, Depressive Symptoms
Reducing Residual Depressive Symptoms With Web-based Mindful Mood Balance
Many patients report residual depressive symptoms despite seemingly successful treatment. With the investigators' previous funding, we developed - Mindful Mood Balance - an online treatment that targets RDS by teaching specific…
- Trial name
- NCT02190968
- Testing
- Usual Depression Care, Mindful Mood Balance
- Where
- United States
- Volunteers
- 460 people
- Sponsor
- University of Toronto
Depression, Recurrent Depression
Rumination Focused Cognitive Behavioral Therapy for Major Depression and Recurrent Depression
Group based cognitive behavioural therapy (CBT) is an effective treatment of depression, however, one third of patients do not respond satisfactorily (McDermut, Miller, \& Brown, 2001), and relapse rates around 30% have been…
- Trial name
- RuCoD (NCT02278224)
- Testing
- Group based rumination focused CBT, Group based CBT
- Where
- Denmark
- Volunteers
- 131 people
- Sponsor
- University of Copenhagen
Major Depressive Disorder, Recurrent, in Remission
Light and Ion Maintenance In Treatment for Depression (LIMIT-D): Feasibility Study
Antidepressants are widely used as first-line treatments for major depressive disorder (MDD). Clinical guidelines recommend 6-24 months of "maintenance" antidepressant treatment, after patients achieve symptom remission, to…
- Trial name
- NCT05423275
- Testing
- Negative ion therapy, Light therapy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of British Columbia
Major Depressive Disorder, Depression, Unipolar
Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence
The purpose of this pilot study is to determine if taking a low dose of naltrexone in addition to an antidepressant medication can help treat relapse or recurrence in people with Major Depressive Disorder (MDD). The U.S.
- Conditions
- Major Depressive Disorder, Depression, Unipolar, Recurrence, Relapse
- Trial name
- NCT01874951
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder, Recurrent
Mechanisms of Mindfulness-Based Cognitive Therapy in the Treatment of Recurrent Major Depressive Disorder
The primary purpose of this study is to investigate neural mechanisms and predictors of treatment outcome in Mindfulness-Based Cognitive Therapy (MBCT) for recurrent Major Depressive Disorder.
- Trial name
- NCT03353493
- Testing
- MBCT, TAU
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- University of Aarhus
Major Depressive Disorder
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
Safety, Tolerability, pharmacokinetics and efficacy of a single administration of COMP360 in participants with recurrent Major Depressive Disorder.
- Trial name
- NCT05733546
- Testing
- Psilocybin
- Where
- 5 sites in United States
- Volunteers
- 102 people
- Sponsor
- COMPASS Pathways
Major Depressive Disorder
The Effect of Fish Oil in Major Depressive Disorder
The whole study was divided into two major parts: (A) the 12-week, double-blind, randomized controlled, parallel omega-3 fatty acid monotherapy study in 60 patients with mild to moderate major depressive disorder.
- Trial name
- NCT00816322
- Testing
- Omega-3 fatty acids
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Science and Technology Council, Taiwan
Depressive Symptoms, Major Depressive Disorder, Recurrent, in Remission
The Effects of the Be Mindful Intervention in Previously Depressed Individuals Experiencing Subclinical Symptoms
This study is designed to help individuals cope with their current depressive symptoms by providing them access to a 4-week online Mindfulness-Based Cognitive Therapy: Be Mindful.
- Trial name
- NCT04740879
- Testing
- Be Mindful
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- State University of New York at Buffalo
Mild Cognitive Impairment, Major Depressive Disorder, Recurrent, In Remission
Prevention of Alzheimer's Disease With CR Plus tDCS in Mild Cognitive Impairment and Depression (PACt-MD)
This 7-year randomized controlled trial will compare the efficacy of non-invasive brain stimulation (trans-cranial Direct Current Stimulation - tDCS) combined with cognitive remediation (CR) versus sham ("placebo") tDCS combined…
- Conditions
- Mild Cognitive Impairment, Major Depressive Disorder, Recurrent, In Remission, Major Depressive Disorder, Single Episode, in Full Remission
- Trial name
- PACt-MD (NCT02386670)
- Testing
- tDCS + CR
- Where
- 5 sites in Canada
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder
Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients
Our hypothesis is that using antidepressants during the ECT has a better efficacy and longer time to relapse/recurrence to the ECT without antidepressants.
- Trial name
- NCT04181567
- Testing
- electroconvulsive therapy, agomelatine
- Where
- Taiwan
- Volunteers
- 97 people
- Sponsor
- Kaohsiung Kai-Suan Psychiatric Hospital